Reversible myocardial dysfunction following intraocular bevacizumab administration

Heart failure has been reported as a rare side effect of bevacizumab, a chemotherapeutic agent, used in the treatment of breast cancer. However, reversible left ventricular systolic dysfunction with a pattern similar to stress-induced cardiomyopathy has not been reported. The etiopathogenesis of stress-induced cardiomyopathy is poorly understood. Given this uncertainty, we should always look out for other potential offenders causing similar presentation, rather than label all of them as "stress-induced".